DK3334457T3 - Humaniserede anti-CCR7-receptorantistoffer - Google Patents
Humaniserede anti-CCR7-receptorantistoffer Download PDFInfo
- Publication number
- DK3334457T3 DK3334457T3 DK16753327.2T DK16753327T DK3334457T3 DK 3334457 T3 DK3334457 T3 DK 3334457T3 DK 16753327 T DK16753327 T DK 16753327T DK 3334457 T3 DK3334457 T3 DK 3334457T3
- Authority
- DK
- Denmark
- Prior art keywords
- humanized anti
- receptor antibodies
- ccr7 receptor
- ccr7
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180415 | 2015-08-10 | ||
| PCT/EP2016/069055 WO2017025569A1 (en) | 2015-08-10 | 2016-08-10 | Humanized anti-ccr7 receptor antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3334457T3 true DK3334457T3 (da) | 2020-09-21 |
Family
ID=53836447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16753327.2T DK3334457T3 (da) | 2015-08-10 | 2016-08-10 | Humaniserede anti-CCR7-receptorantistoffer |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10640565B2 (da) |
| EP (1) | EP3334457B1 (da) |
| JP (1) | JP6844864B2 (da) |
| KR (1) | KR102663440B1 (da) |
| CN (1) | CN109069620B (da) |
| AU (1) | AU2016305283B2 (da) |
| CA (1) | CA2994214C (da) |
| DK (1) | DK3334457T3 (da) |
| EA (1) | EA037397B1 (da) |
| ES (1) | ES2828368T3 (da) |
| HU (1) | HUE051920T2 (da) |
| IL (1) | IL257359B (da) |
| MX (1) | MX394165B (da) |
| PT (1) | PT3334457T (da) |
| SI (1) | SI3334457T1 (da) |
| WO (1) | WO2017025569A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016305283B2 (en) * | 2015-08-10 | 2022-05-26 | Pepmab B.V. | Humanized anti-CCR7 receptor antibodies |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| CN113557244A (zh) * | 2018-12-18 | 2021-10-26 | 弹射器治疗有限公司 | 预防或治疗移植物抗宿主病(GvHD)的抗CCR7 mAb的用途 |
| WO2020206233A1 (en) * | 2019-04-04 | 2020-10-08 | Vanderbilt University | Therapeutic antibodies for treating lung cancer |
| EP4041764A1 (en) * | 2019-10-09 | 2022-08-17 | Catapult Therapeutics B.V. | Use of an anti-ccr7 antibody in combination therapies with a btk inhibitor and/or bcl2- inhibitor for treating hematological malignancies |
| US20230181756A1 (en) * | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| EP4173636A4 (en) * | 2020-06-30 | 2024-08-28 | Shionogi & Co., Ltd | Combined use of anti-ccr8 antibody and chemotherapeutic agent |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| CN112957472B (zh) * | 2021-02-05 | 2021-11-16 | 无锡市第五人民医院 | 靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| KR102748862B1 (ko) * | 2022-05-19 | 2025-01-02 | 국민대학교 산학협력단 | Ccr7의 활성 조절 항체 |
| CN116284419B (zh) * | 2023-02-07 | 2024-10-11 | 深圳市先康达生命科学有限公司 | 靶向人gucy2c蛋白的单克隆抗体及其应用 |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| JP7747395B2 (ja) | 2023-03-28 | 2025-10-01 | 株式会社エヌビィー健康研究所 | 抗体、核酸、細胞、及び医薬 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN119390838B (zh) * | 2024-05-29 | 2025-06-10 | 锐胜科生物医药(上海)有限公司 | 一种靶向ccr7的纳米抗体及其制备与应用 |
| CN119236085A (zh) * | 2024-12-05 | 2025-01-03 | 北京大学第三医院（北京大学第三临床医学院） | 可治疗系统性硬化病的趋化因子配体19抑制剂的应用 |
| CN120241998B (zh) * | 2025-04-02 | 2025-10-28 | 广东优赛生物医药科技有限公司 | 一种药物组合物及其在调降血糖血脂中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| WO2007003216A1 (en) * | 2005-07-06 | 2007-01-11 | Universidad Autónoma de Madrid | Anti-ccr7 receptor antibodies for the treatment of cancer |
| WO2009139853A2 (en) * | 2008-05-14 | 2009-11-19 | Kim, Eldar | Human monoclonal antibodies against human chemokine receptor ccr7 |
| EP2623592B1 (en) | 2010-09-28 | 2019-05-15 | NB Health Laboratory Co. Ltd. | Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier |
| US20150344580A1 (en) * | 2012-06-05 | 2015-12-03 | Eldar Kim | Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7 |
| JP6469644B2 (ja) * | 2013-03-15 | 2019-02-13 | アムジエン・インコーポレーテツド | 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物 |
| AU2016305283B2 (en) * | 2015-08-10 | 2022-05-26 | Pepmab B.V. | Humanized anti-CCR7 receptor antibodies |
-
2016
- 2016-08-10 AU AU2016305283A patent/AU2016305283B2/en active Active
- 2016-08-10 EP EP16753327.2A patent/EP3334457B1/en active Active
- 2016-08-10 PT PT167533272T patent/PT3334457T/pt unknown
- 2016-08-10 ES ES16753327T patent/ES2828368T3/es active Active
- 2016-08-10 US US15/751,169 patent/US10640565B2/en active Active
- 2016-08-10 EA EA201890447A patent/EA037397B1/ru unknown
- 2016-08-10 CA CA2994214A patent/CA2994214C/en active Active
- 2016-08-10 JP JP2018506333A patent/JP6844864B2/ja active Active
- 2016-08-10 WO PCT/EP2016/069055 patent/WO2017025569A1/en not_active Ceased
- 2016-08-10 KR KR1020187006973A patent/KR102663440B1/ko active Active
- 2016-08-10 SI SI201630946T patent/SI3334457T1/sl unknown
- 2016-08-10 CN CN201680059274.5A patent/CN109069620B/zh active Active
- 2016-08-10 DK DK16753327.2T patent/DK3334457T3/da active
- 2016-08-10 MX MX2018001596A patent/MX394165B/es unknown
- 2016-08-10 HU HUE16753327A patent/HUE051920T2/hu unknown
-
2018
- 2018-02-05 IL IL257359A patent/IL257359B/en unknown
-
2020
- 2020-03-10 US US16/813,780 patent/US11254749B2/en active Active
-
2022
- 2022-01-18 US US17/577,493 patent/US12122838B2/en active Active
-
2024
- 2024-10-18 US US18/919,472 patent/US20250092147A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109069620A (zh) | 2018-12-21 |
| ES2828368T3 (es) | 2021-05-26 |
| US10640565B2 (en) | 2020-05-05 |
| US20180237529A1 (en) | 2018-08-23 |
| EA201890447A1 (ru) | 2018-11-30 |
| CA2994214C (en) | 2024-03-12 |
| US20200362043A1 (en) | 2020-11-19 |
| JP6844864B2 (ja) | 2021-03-17 |
| CA2994214A1 (en) | 2017-02-16 |
| CN109069620B (zh) | 2022-04-26 |
| EP3334457B1 (en) | 2020-08-26 |
| US11254749B2 (en) | 2022-02-22 |
| KR20180030931A (ko) | 2018-03-26 |
| AU2016305283B2 (en) | 2022-05-26 |
| US20220135693A1 (en) | 2022-05-05 |
| BR112018002877A2 (en) | 2018-11-06 |
| MX2018001596A (es) | 2018-05-02 |
| US20250092147A1 (en) | 2025-03-20 |
| IL257359B (en) | 2022-03-01 |
| WO2017025569A1 (en) | 2017-02-16 |
| JP2018522568A (ja) | 2018-08-16 |
| PT3334457T (pt) | 2020-09-24 |
| SI3334457T1 (sl) | 2021-01-29 |
| MX394165B (es) | 2025-03-24 |
| EA037397B1 (ru) | 2021-03-24 |
| US12122838B2 (en) | 2024-10-22 |
| EP3334457A1 (en) | 2018-06-20 |
| HUE051920T2 (hu) | 2021-03-29 |
| KR102663440B1 (ko) | 2024-05-07 |
| AU2016305283A1 (en) | 2018-02-22 |
| IL257359A (en) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280917B (en) | Cs1 targeted chimeric antigen receptor-modified t cells | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL257359B (en) | Humanized antibodies against the ccr7 receptor | |
| HUE047929T2 (hu) | Kiméra antigén receptor | |
| EP3532489A4 (en) | ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES | |
| IL258502A (en) | Chimeric antigen receptors targeted to psca | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3332006T5 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| EP3319984C0 (en) | TAU LINKING ANTIBODIES | |
| KR20180085002A (ko) | 인간화된 항-cll-1 항체 | |
| EP3356420C0 (en) | MULTI-SPECIFIC ANTIBODIES | |
| EP3182987C0 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| IL256097A (en) | Antibody epitope | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3452513T3 (da) | Humaniserede anti-il-ir3-antistoffer | |
| HUE061076T2 (hu) | Humanizált anti-C1s ellenanyagok alkalmazási eljárások | |
| IL256579A (en) | Human antibodies | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| IL248402B (en) | Humanized antibodies against ceacam1 | |
| DK3116908T3 (da) | Humaniserede kir3dl2-antistoffer | |
| PT3215530T (pt) | Anticorpos de il-6 melhorados | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 |